Download - iSyPeM2 - Nano-Tera 2016
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
1/33
Administration and monitoring of medical treatments
1
Intelligent Systems for Personalized MedicineISyPeM II
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
2/33
2
Intelligent Systems for Personalized MedicineISyPeM II
dministration and monitoring of medical treatments
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
3/33
3
Intelligent Systems for Personalized MedicineISyPeM II
dministration and monitoring of medical treatments
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
4/33
4
s o medical treatment or which monitoring is highly critical
IV ANTIBIOTIC
I!!"NO"##$%IV%
&$"'
CANC%$ TA$'%T%&T(%$A#I%
time after dose (hrs)
I m
a t i n i b e x p o s u r e
( n g / m l )
#atient
Courtesy of N. Widmer
Syva Rapidest!
"nly#ualitative$%rugconcentrationneeds to be&uanti'ed it
*+, accuracyfor %M
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
5/33
)
Towards distri*+ted *ioanalytic
IV ANTIBIOTIC
I!!"NO"##$%IV%
&$"'
CANC%$ TA$'%T%&T(%$A#I% iSA- Abbott
.lonitStMicroelectronicscobas! ab0in0a
tube
Roce%iagnostics
Accu0.e1 productlines2Roce %iagnostics
op benc
3and0eld
Physiological parameters, DNA
analysis
s o medical treatment or which monitoring is highly critical
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
6/33
Reduce volume samplesMonitoring of treatmentis often needed inneborn and cild care
.ompact- a4ordableanalytical systems
Measurement performed atte M%integrated it decisions+pport sotware
Interaction andInteroperability
5ater data for decisionon dosage and enricpopulation data
,
6I".37MI.A/A8A9I.A .3A7857S
6I".37MI.A/A8A9I.A .3A7857S
%AA I87RPR7AI"8 A8% MA8A57M78 .3A7857S
Intelligent Systems for Personalized MedicineISyPeM II
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
7/33
Affordability of the analytical system
Meet the microsample challenge
-
Abbott :Arcitect ci;0M SeguraM 5eiser
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
8/33
Affordability of the analytical system
Meet the microsample challenge
0
Abbott :Arcitect ci;0M SeguraM 5eiser
Iy#e! II demonstratoro0cost?ully integrated6ased on 3ig sensitive ?PIA@or1s on capillaries
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
9/33
Microsample analytics in capillaries
#lasma e1traction rom whole
*lood
9ield outperforms any passive on0cip
metod reported to date2 7xtractionfrom eection2
ttpB//dbs0system2c
Renaud ab
2
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
10/33
3#IA o To*ramycin perormed in glass
microcapillaries+ared glass capillary
ttpB//dbs0system2c
5// 6m
= < C D ; *= *<
=2*C=
=2*D=
=2*;=
=2
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
11/33
Lack of availability of ligands for drug
molecules
77
" 6 R A M 9
. I 8
I M A I 8 I 6
A . R " I M H S
• %rugs are small molecules
• ey can ave very di4erent solubility andbiocemical and metabolic caracteristics
• In vivo raised antibody against drugs avepoor anities and in some case are notavailable at all
@e develop in vitro approaces for teselection of ligands for di4erent classes
of drugs
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
12/33
In vitro selection of aptamers
" 6 R A M 9
. I 8
5uiducci ab
%8A aptamers canbe obtained in afe steps tat arebetter or e&ual toexisting R8A
aptamers
?unctional in serumand proved onpatient samples-meeting te clinical
range
Speci'citydemonstrated
Metod can be
applied to di4erentdrugs
.lin2 Parmac2
: CCTTACCTA''T'TA': )8)8 :''AAT''ATCCACATC:
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
13/33
Measuring Tobramycin concentration
from serum on a palm-sized devices
5uiducci ab
" 6 R A M 9
. I 8
52 et al2 Analytical .emistry- April
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
14/33
In vitro selection of antibodies
A . R " I M H S
3einis a
?irst in vitroselection ofantibodiesagainst
acrolimus everperformed
o approaceddeployed tocompetition
assay
Peptidemacrocycles0
based approacfor assays
>0M Segura
74.2 3einis- 6icyclic peptide page display- *=t Peptide erapeutics Symposium-
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
15/33
D T INT!"!T TI#N
ND M N $MNT
7)
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
16/33
Drug decision support system
developed by I%y"eM II partners
%iv2 .lin2 Parmac2
9ann oma
8o in use at
.3HK andconnected itM"IS database
argelyoutperformingany existingsupport systems
Kalidation and.linical trials inprogress forcerti'cation andcommercialization
?I grant for start0up creationBttpB//2fondation0't2c
ab Innovation Aard- ausanne
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
17/33
Meta-analysis approaches to build
population pharmacokinetics models
%iv2 .lin2 Parmac2
Br J Clin Pharmacol. 20!
No"#$%&'()0*0+0
.onsolidation of
population studies for %M
Statistical combinationof independentpopulation studies
I M A I 8
I 6
7 ? A K I R
7 8 L
A M I 8 " 5 9 . " S I % 7 S
7-
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
18/33
"&" approach for data storage
#+*lishD+*scri*e
## Networ;
Contri*+tor$&B
Contri*+tor$&B
&Bmetadata
&B
E+eryD%1change
&ata
uple+center
Negotiate
Initiator
A7
Cryptographic
!od+le
Anonymi>ation!od+le
$&B
8o centralizedsystem fordata storage
.ontributorscan sareteir data andgetanonymized
data from teoters
:Multi0Agent System for %ynamic %ataAggregation in Medical Researc A2%ubovits1aya- K2 Hrovi- I2 6arba- O2Aberer- M2 I2 Scumacer- in preparation%ubovits1aya- A2 Privacy PreservingInteroperability for PersonalizedMedicine- inB Siss Medical Informatics-Siss Society for Medical Informatics-
Sitzerland-
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
19/33
#utput and outlook
ore tan *+ peer revieed papers publised (only ISyPeM II)
irst demonstrator is functional
I on going it a Parma company (%ebioparm International)
terest in te diagnostics 'eld
72
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
20/33
/
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
21/33
7
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
22/33
Therapeutic Drug Monitoring Today
Abbott :Arcitect ci;
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
23/33
'ioanalytical systems for diagnostics
and monitoring
Syva Rapidest!
EMIT (Enyme mu!ti"!ied
immunoassay te#hni$ue)
iSA- Abbott
.lonitStMicroelectronicscobas! ab0in0a
tube
Roce%iagnostics
Accu0.e1 productlines2Roce %iagnostics
op benc
3and0eld
ysiological parameters- %8A analysis 7R %rug of abuse tests
"nly #ualitative$%rug concentrationneeds to be &uanti'edit *+, accuracy for %M
5
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
24/33
4
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
25/33
)
I% " M bli d b d
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
26/33
I%y"eM( nabling drug-based
therapeutic drug monitoring(
iSA- AbbottAccu0.e1 productlines2Roce %iagnostics
3and0eld
ysiological parameters- %8A analysis
I%y"eM integrated
approach to TDM
e3ealtstandards
%atasecurity
.artridge
it stablereagents
o samplevolume
Supported
Interpretationfor nonspecialists
At te clinicand outside
.lonitStMicroelectronicscobas! ab0in0a
tube
Roce%iagnostics
op benc
,
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
27/33
I%y"eM II) #b*ectives
%e&e!o" and demonstrate the feasi'i!ity of in vitro selection te#hni$ues to identify suita'!e
"ro'es for dru mo!e#u!es
A#hie&e microvolume "ro#essin and ana!ysis
%e&e!o" no&e! compact and full!inte"rated assas "ro&in their • Sta'i!ity of mo!e#u!es in #om"!e matri and in "resen#e of sam"!e treatment
reaents• S"e#ifi#ity
• A##ura#y
E$ui" !o#a! #!ini#a! institutions and se!e#ted #a'inets *ith #ertified decision support
sstems for dru dosae• Lare!y out"erformin eistin too!s for usa'i!ity and &a!ue of e!a'oration
a""roa#hes em"!oyed+• Conne#ted *ith !o#a! data'ases, se#ure and #onne#ted in a PP net*or to enri#h
"harma#oineti# data'ases
%evelop a top0benc stand0alone proof0of0conceptdemonstrator for in vitro &uantitative analysis of terapeutic
drug from ole blood2 e consortium is no focusing on antibiotics andimmunosuppressant drugs2
"ur metodology
-
M t t i i t i ti f
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
28/33
Measurement system) miniaturization of
the assay
. ) c m
/ cm
+orescence #olari>ation Imm+noassay
" 6 R A M
9 . I 8
.ompetitive assay(ig sensitivity)
%esigned for lovolumes (focalized)
?unctional on ells-tested on capillariesand paper
Renaud ab
>0M SeguraM2 PfeiferM2 5eiser
0
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
29/33
"rogress of demonstrator
IntegratedPartially integrated8ot integrated 2
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
30/33
'A+, " slides
5/
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
31/33
EImatini*G
Therape+tic dr+g monitoring (%M) forimatinib as been suggested to impro?eeGcacy- assess compliance- and e?al+atedr+g:dr+g interactionseng et al., herapeutic Drug -onitoring. !&()%'+*$,/eruary 202.
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
32/33
#$%& for tacrolimus 'DM(urrent status and ne)t steps
-
8/18/2019 iSyPeM2 - Nano-Tera 2016
33/33
enrico accastelli@epf
5otta K- 6uclin - .sa1a .- @idmer 82 Systematic revie of populationparmaco1inetic analyses
Po"u!ation P. Meta-ana!ysis of Imatini'
P+
P+
P